R.PR
REGISTERED-PRINCIPAL REGISTER
04/05/2022
Back to search
Official data from USPTO
SYNGENE SYNVENT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
04/05/2022
Trademark type
Combined
Nice classes
42, 44
Filing date
07/21/2020
Registration date
04/05/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/05/2022
Last transaction
04/05/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
08/11/2021
First use in commerce
08/11/2021
Drawing code
3
Owner type
99
Owner location
Karnataka, IN
Examiner
BLACK, MILDRED
Law office
N30
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the word "SYNGENE", in a smaller font, above the right half of the word "SYNVENT", the word "SYNVENT" having the the outline of the letter "V" within a solid circle.
Holders and representatives
Holders
Syngene International Limited
Representatives
Mark A. Watkins VORYS, SATER, SEYMOUR AND PEASE LLP
Technical classification
Nice Classes
Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Scientific research and custom synthesis; scientific and clinical research in the field of medicinepharmaceuticalnutraceuticals; scientific research and development; custom design and development of chemical reagents and biochemical assays; laboratory testing services for research purposes; testing of pharmaceuticals; chemical engineering; drug discovery services; pharmaceutical drug development services; pharmaceutical products development; development of pharmaceutical preparations and medicines; scientific study and research in the field of reproductionhusbandrygeneral health of animal; biotechnology research for determining the neuronal survival of molecules in animal models; research and development services in the field of antibodiesantibody technology; custom design and development of chemical reagents and biochemical assays; designengineeringresearchdevelopment and testing services in the field of polymeric materialspolymer synthesismaterials customization for medicalscientifictechnological applications; toxicology services; toxicity analysis; toxicity testing for research purposes; conducting clinical trials for scientific research for others; conducting clinical trials for others in the field of pharmaceutical products; providing medical and scientific research information in the field of clinical trials; conducting early evaluations in the field of new pharmaceuticals; DNA analysis services for scientific research purposes; laboratory research in the field of gene expression; blood analysis services for scientific research purposes; analysis of human tissues for medical research; scientific services relating to the isolation and cultivation of human tissues and cells for research purposes; preparation of reports relating to scientific and technical research; analysis in the field of molecular biology; contract research services relating to molecular sciences; biological cloning services; structural and functional analysis of genomes; scientific and medical laboratory services; services of a chemical and/or biological laboratory; laboratory research services relating to pharmaceuticals; research and development and consultation related thereto in the field of antibodiesantibody technologychemistrybioinformaticsbiomedical devicesbiologicsbiotechnologybiotherapeuticsbiologybiochemical preparationscell linechemoinformaticgenetics and genetic engineeringgene expression systemsin vitro researchinhalation pharmaceuticalsmolecular sciencesmicro-organismsnutritionophthalmic preparationspharmacogeneticspharmacokineticspharmacologypharmaceuticalspolymerpeptide synthesisproteinsolid state characterization; toxicokinetic analysis and toxicology services; scientific and technological servicesscientific researchdevelopmentanalysistestingengineeringextractionsynthesispurification and production in the field of antibodiesactive pharmaceutical ingredients (API)biomoleculescell bank characterizationchiralitychromosome aberrationclinical chemistrycloning vectorcyclotidesDNAflow cytometrygas chromatography mass spectrometrygenesimmuno-pharmaceuticalsin vitro irritationlarge moleculeliquid chromatography mass spectrometrymicrobialsmonomersnanoparticlesnatural productspeptidesproteinsRNAsupercritical fluid chromatographysmall molecules and vaccines; none of the aforesaid services relating to gel imaging and gel analysis applications and none of the aforesaid services in the field of agriculturehorticulture and forestry
Class 44
Medical diagnostic testingmonitoring and reporting services; preparation of reports relating to medical matters; services for the testing of urine; pathology services for medical and diagnostic purposes
Publications
History of USPTO decisions and trademark events.
26 publications found
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
03/04/2022
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
03/03/2022
SUPC
STATEMENT OF USE PROCESSING COMPLETE
02/15/2022
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
02/14/2022
IUAF
USE AMENDMENT FILED
01/27/2022
EISU
TEAS STATEMENT OF USE RECEIVED
01/27/2022
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
07/27/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/01/2021
PUBO
PUBLISHED FOR OPPOSITION
06/01/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/12/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/29/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
04/29/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/29/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
04/29/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/29/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/09/2020
GNRT
NON-FINAL ACTION E-MAILED
11/09/2020
CNRT
NON-FINAL ACTION WRITTEN
11/09/2020
DOCK
ASSIGNED TO EXAMINER
11/04/2020
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
08/19/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/18/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
07/29/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/29/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
07/29/2020
NWAP
NEW APPLICATION ENTERED
07/24/2020
Continuous trademark protection
Get notified about every new filing that threatens SYNGENE SYNVENT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.